Pinetree Therapeutics Raises $47M to Advance Protein Degraders
Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series B financing....
